{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:17:56Z","timestamp":1793578676446,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2025J01122"],"award-info":[{"award-number":["2025J01122"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Provincial Clinical Research Center for Hematological Malignancies","award":["2020Y2006"],"award-info":[{"award-number":["2020Y2006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07112-y","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:43:39Z","timestamp":1781070219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study"],"prefix":"10.1007","volume":"105","author":[{"given":"Yongzhi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nainong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mincui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"20","key":"7112_CR1","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","volume":"127","author":"N Duployez","year":"2016","unstructured":"Duployez N, Marceau-Renaut A, Boissel N et al (2016) Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood 127(20):2451\u20132459. https:\/\/doi.org\/10.1182\/blood-2015-12-688705","journal-title":"Blood"},{"key":"7112_CR2","doi-asserted-by":"publisher","first-page":"204062072513300","DOI":"10.1177\/20406207251330064","volume":"16","author":"Z Hu","year":"2025","unstructured":"Hu Z, Tang X, Chen F et al (2025) Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics. Ther Adv Hematol 16:20406207251330064. https:\/\/doi.org\/10.1177\/20406207251330064","journal-title":"Ther Adv Hematol"},{"issue":"20","key":"7112_CR3","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1182\/bloodadvances.2019000404","volume":"3","author":"N Shiba","year":"2019","unstructured":"Shiba N, Yoshida K, Hara Y et al (2019) Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv 3(20):3157\u20133169. https:\/\/doi.org\/10.1182\/bloodadvances.2019000404","journal-title":"Blood Adv"},{"issue":"16","key":"7112_CR4","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.3390\/cancers15164171","volume":"15","author":"D Tomizawa","year":"2023","unstructured":"Tomizawa D, Tsujimoto SI (2023) Risk-stratified therapy for pediatric acute myeloid leukemia. Cancers (Basel) 15(16):4171. https:\/\/doi.org\/10.3390\/cancers15164171","journal-title":"Cancers (Basel)"},{"issue":"3","key":"7112_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/jcm11030504","volume":"11","author":"D Reinhardt","year":"2022","unstructured":"Reinhardt D, Antoniou E, Waack K (2022) Pediatric acute myeloid leukemia-past, present, and future. J Clin Med 11(3):504. https:\/\/doi.org\/10.3390\/jcm11030504","journal-title":"J Clin Med"},{"key":"7112_CR6","doi-asserted-by":"publisher","first-page":"115705","DOI":"10.1016\/j.bcp.2023.115705","volume":"215","author":"N Tosic","year":"2023","unstructured":"Tosic N, Marjanovic I, Lazic J (2023) Pediatric acute myeloid leukemia: insight into genetic landscape and novel targeted approaches. Biochem Pharmacol 215:115705. https:\/\/doi.org\/10.1016\/j.bcp.2023.115705","journal-title":"Biochem Pharmacol"},{"issue":"J","key":"7112_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12885-023-10965-5","volume":"16","author":"KY Qiu","year":"2023","unstructured":"Qiu KY, Liao XY, Li Y et al (2023) Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv (16). BMC Cancer 16(J):476. https:\/\/doi.org\/10.1186\/s12885-023-10965-5","journal-title":"BMC Cancer"},{"issue":"12","key":"7112_CR8","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/leu.2013.153","volume":"27","author":"D Tomizawa","year":"2013","unstructured":"Tomizawa D, Tawa A, Watanabe T et al (2013) Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. Leukemia 27(12):2413\u20132416. https:\/\/doi.org\/10.1038\/leu.2013.153","journal-title":"Leukemia"},{"issue":"4","key":"7112_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/10428194.2017.1361025","volume":"59","author":"X Chen","year":"2018","unstructured":"Chen X, Dou H, Wang X et al (2018) KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. Leuk Lymphoma 59(4):829\u2013836. https:\/\/doi.org\/10.1080\/10428194.2017.1361025","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"7112_CR10","doi-asserted-by":"publisher","first-page":"e30791","DOI":"10.1002\/pbc.30791","volume":"71","author":"S Srinivasan","year":"2024","unstructured":"Srinivasan S, Dhamne C, Patkar N et al (2024) KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1 [J]. Pediatr Blood Cancer 71(2):e30791. https:\/\/doi.org\/10.1002\/pbc.30791","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"7112_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/sj.leu.2404995","volume":"22","author":"LY Shih","year":"2008","unstructured":"Shih LY, Liang DC, Huang CF et al (2008) Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 22(2):303\u2013307. https:\/\/doi.org\/10.1038\/sj.leu.2404995","journal-title":"Leukemia"},{"issue":"6","key":"7112_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.21037\/tp-20-102","volume":"9","author":"J Fan","year":"2020","unstructured":"Fan J, Gao L, Chen J, Hu S (2020) Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. Transl Pediatr 9(6):726\u2013733. https:\/\/doi.org\/10.21037\/tp-20-102","journal-title":"Transl Pediatr"},{"issue":"1","key":"7112_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","volume":"4","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kawashima N, Atsuta Y et al (2020) Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv 4(1):66\u201375. https:\/\/doi.org\/10.1182\/bloodadvances.2019000709","journal-title":"Blood Adv"},{"issue":"16","key":"7112_CR14","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","volume":"25","author":"K Tarlock","year":"2019","unstructured":"Tarlock K, Alonzo TA, Wang YC et al (2019) Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res 25(16):5038\u20135048. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1897","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7112_CR15","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood-2005-08-3408","volume":"107","author":"A Shimada","year":"2006","unstructured":"Shimada A, Taki T, Tabuchi K et al (2006) KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 107(5):1806\u20131809. https:\/\/doi.org\/10.1182\/blood-2005-08-3408","journal-title":"Blood"},{"issue":"5","key":"7112_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/leu.2013.339","volume":"28","author":"E Manara","year":"2014","unstructured":"Manara E, Bisio V, Masetti R et al (2014) [J] Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002\/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 28(5):1132\u20131134. https:\/\/doi.org\/10.1038\/leu.2013.339","journal-title":"Leukemia"},{"key":"7112_CR17","doi-asserted-by":"publisher","first-page":"104770","DOI":"10.1016\/j.critrevonc.2025.104770","volume":"212","author":"A Javidan","year":"2025","unstructured":"Javidan A, Azarboo A, Jalali S et al (2025) Secondary mutational and cytogenetic alterations in core binding factor\u2013acute myeloid leukemia (CBF-AML): A systematic review and meta-analysis. Crit Rev Oncol Hematol 212:104770. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104770","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"7112_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00277-024-06182-0","volume":"104","author":"S Yu","year":"2025","unstructured":"Yu S, Yang S, Hu L et al (2025) Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia. Ann Hematol 104(2):997\u20131006. https:\/\/doi.org\/10.1007\/s00277-024-06182-0","journal-title":"Ann Hematol"},{"issue":"12","key":"7112_CR19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.leukres.2014.09.017","volume":"38","author":"YZ Qin","year":"2014","unstructured":"Qin YZ, Zhu HH, Jiang Q et al (2014) Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. Leuk Res 38(12):1435\u20131440. https:\/\/doi.org\/10.1016\/j.leukres.2014.09.017","journal-title":"Leuk Res"},{"issue":"12","key":"7112_CR20","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1182\/blood-2009-09-241075","volume":"115","author":"JA Pollard","year":"2010","unstructured":"Pollard JA, Alonzo TA, Gerbing RB et al (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115(12):2372\u20132379. https:\/\/doi.org\/10.1182\/blood-2009-09-241075","journal-title":"Blood"},{"issue":"11","key":"7112_CR21","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"G Borthakur","year":"2022","unstructured":"Borthakur G, Ravandi F, Patel K et al (2022) Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427\u20131434. https:\/\/doi.org\/10.1002\/ajh.26700","journal-title":"Am J Hematol"},{"issue":"9","key":"7112_CR22","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/sj.leu.2403870","volume":"19","author":"BF Goemans","year":"2005","unstructured":"Goemans BF, Zwaan CM, Miller M et al (2005) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19(9):1536\u20131542. https:\/\/doi.org\/10.1038\/sj.leu.2403870","journal-title":"Leukemia"},{"issue":"10","key":"7112_CR23","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/ajh.23795","volume":"89","author":"G Borthakur","year":"2014","unstructured":"Borthakur G, Cortes JE, Estey EE et al (2014) Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89(10):964\u2013968. https:\/\/doi.org\/10.1002\/ajh.23795","journal-title":"Am J Hematol"},{"issue":"1","key":"7112_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, Dinardo CD, Kadia TM et al (2025) Acute myeloid leukemia management and research in 2025. CA Cancer J Clin 75(1):46\u201367. https:\/\/doi.org\/10.3322\/caac.21873","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"7112_CR25","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1200\/JCO.23.00943","volume":"42","author":"NH Russell","year":"2024","unstructured":"Russell NH, Wilhelm-Benartzi C, Othman J et al (2024) Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol 42(10):1158\u20131168. https:\/\/doi.org\/10.1200\/JCO.23.00943","journal-title":"J Clin Oncol"},{"issue":"27","key":"7112_CR26","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol 31(27):3360\u20133368. https:\/\/doi.org\/10.1200\/JCO.2012.47.4874","journal-title":"J Clin Oncol"},{"issue":"4","key":"7112_CR27","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","volume":"39","author":"CD Dinardo","year":"2025","unstructured":"Dinardo CD, Jen WY, Takahashi K et al (2025) Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854\u2013863. https:\/\/doi.org\/10.1038\/s41375-025-02531-8","journal-title":"Leukemia"},{"issue":"1","key":"7112_CR28","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1111\/bjh.18844","volume":"202","author":"A Doan","year":"2023","unstructured":"Doan A, Huang HKT, Hadar AJ et al (2023) Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population. Br J Haematol 202(1):e3\u2013e6. https:\/\/doi.org\/10.1111\/bjh.18844","journal-title":"Br J Haematol"},{"issue":"5","key":"7112_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ajh.26510","volume":"97","author":"L Pommert","year":"2022","unstructured":"Pommert L, Schafer ES, Malvar J et al (2022) Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed\/refractory AML: report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol 97(5):613\u2013622. https:\/\/doi.org\/10.1002\/ajh.26510","journal-title":"Am J Hematol"},{"issue":"1","key":"7112_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12885-023-11784-4","volume":"24","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Pan L, Li J et al (2024) Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia. BMC Cancer 24(1):46. https:\/\/doi.org\/10.1186\/s12885-023-11784-4","journal-title":"BMC Cancer"},{"issue":"20","key":"7112_CR31","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"3","key":"7112_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/JLB.5A0721-361R","volume":"112","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zheng Y, Hong Y et al (2022) Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic. J Leukoc Biol 112(3):513\u2013522. https:\/\/doi.org\/10.1002\/JLB.5A0721-361R","journal-title":"J Leukoc Biol"},{"issue":"9","key":"7112_CR33","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2013.186","volume":"27","author":"C Allen","year":"2013","unstructured":"Allen C, Hills RK, Lamb K et al (2013) The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 27(9):1891\u20131901. https:\/\/doi.org\/10.1038\/leu.2013.186","journal-title":"Leukemia"},{"issue":"36","key":"7112_CR34","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2015.61.1947","volume":"33","author":"K Klein","year":"2015","unstructured":"Klein K, Kaspers G, Harrison CJ et al (2015) Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the international Berlin\u2013Frankfurt\u2013M\u00fcnster study group. J Clin Oncol 33(36):4247\u20134258. https:\/\/doi.org\/10.1200\/JCO.2015.61.1947","journal-title":"J Clin Oncol"},{"issue":"5","key":"7112_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00277-019-03624-y","volume":"98","author":"HJ Shin","year":"2019","unstructured":"Shin HJ, Min WS, Min YH et al (2019) Different prognostic effects of core-binding factor positive AML with Korean AML registry data. Ann Hematol 98(5):1135\u20131147. https:\/\/doi.org\/10.1007\/s00277-019-03624-y","journal-title":"Ann Hematol"},{"issue":"4","key":"7112_CR36","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3324\/haematol.2021.278645","volume":"107","author":"S Kayser","year":"2022","unstructured":"Kayser S, Kramer M, Mart\u00ednez-Cuadr\u00f3n D et al (2022) Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica 107(4):836\u2013843. https:\/\/doi.org\/10.3324\/haematol.2021.278645","journal-title":"Haematologica"},{"issue":"4","key":"7112_CR37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3324\/haematol.2021.279409","volume":"107","author":"S Loo","year":"2022","unstructured":"Loo S, Wei AH (2022) FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue. Haematologica 107(4):783\u2013784. https:\/\/doi.org\/10.3324\/haematol.2021.279409","journal-title":"Haematologica"},{"issue":"3","key":"7112_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3324\/haematol.2023.283765","volume":"109","author":"H Hasle","year":"2024","unstructured":"Hasle H, Juul-Dam KL (2024) Maximal benefit of minimal residual disease monitoring in pediatric acute myeloid leukemia. Haematologica 109(3):701\u2013703. https:\/\/doi.org\/10.3324\/haematol.2023.283765","journal-title":"Haematologica"},{"issue":"1","key":"7112_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-023-02083-9","volume":"38","author":"M Zaliova","year":"2024","unstructured":"Zaliova M, Zuna J, Winkowska L et al (2024) Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study. Leukemia 38(1):21\u201330. https:\/\/doi.org\/10.1038\/s41375-023-02083-9","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"7112_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajh.27482","volume":"100","author":"NJ Short","year":"2025","unstructured":"Short NJ, Dillon R (2025) Measurable residual disease monitoring in AML: prospects for therapeutic decision-making and new drug development. Am J Hematol 100(Suppl 2):5\u201315. https:\/\/doi.org\/10.1002\/ajh.27482","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07112-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:54Z","timestamp":1789465374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07112-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7112"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07112-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8473547\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical Approval No obtained from the Fujian Medical University Union Hospital Institutional Review Board (Approval No.: 2025KY666), with a waiver of informed consent granted in accordance with the national regulations and the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"371"}}